关于初创公司的融资，有很多信息，但对于后期公司的进一步融资，则没有那么多。我们听取了他的建议Marian Nakada, VP of Venture Investments at Johnson & Johnson Innovationas she focused on pharmaceutical investments into East Coast companies. She lent some insightful recommendations for continued financing for later-stage companies.
玛丽安说：“要吸引投资者，你必须有一个清晰而有说服力的叙述，不仅要以易于理解的方式阐明这一科学，而且要传达出公司为什么有潜力创造一个游戏规则改变者，而不仅仅是提供增量收益的承诺。”。
“Sometimes this requires engaging external experts or consultants to help you refine the pitch. Once refined, it’s then crucial to identify the right investors to engage who can lead the first round, as they often want to determine who they syndicate with. It’s also important to not engage multiple investors at once since you can learn from the feedback and improve upon your pitch with each investor meeting. Also, reach out to established funds or crossover investors who you know and that are actively investing, and treat the financing as something that will be oversubscribed and for which you will be selective in sharing the pitch. This avoids the impression that the deal is being shopped to everyone which can be a turnoff to investors.”
[Read the article with Head of J&J Innovation, EMEA, Sir Harpal Kumar,向初创企业提供建议]
此外，她认为，对于寻找合作伙伴的后期公司，有一种战略方法。
“Know the right network of business development leads and stay ahead of any evolving strategies or changes in focus among their respective pharma and biotech companies that could impact your pitch approach,” Marian said. “Stay in regular touch with them, such as every six months, to provide any relevant updates on your company. They will be your advocates once you have data that drives them to engage. Meet them in person and forge relationships—the world is small and they could move to a different pharma/biotech where you can continue to leverage that relationship there.”
Lately, there has been some concern in the biotech sector with some corporate finance leaders preparing for a recession to hit within 18 months. However, Marian sees a positive outlook for the future.
她说：“如果风险投资融资和IPO退出很难实现，这可能是BD或并购的一个机会，条件优惠。”。“这也可能推动公司估值的重新调整，因为在没有IPO作为替代资金来源的情况下，风投可能拥有更多的杠杆。”
To learn more, join Marian at Biotech Showcase™在旧金山she will be featured on the January 8 panel: “The financing frenzy: Is it truly the best of times?”
